Clinical Trials for Squamous Cell Carcinoma Of The Skin

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic cutaneous squamous cell carcinoma refractory to anti-PD-1 therapy receive intravenous ivonescimab every 21 days. Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF-A.

ClinicalTrials.gov ID: NCT06567314

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressive recurrent or metastatic solid tumors across 13 cohorts receive intravenous ifinatamab deruxtecan, generally every 3 weeks. This investigational antibody–drug conjugate targets B7-H3 (CD276) and delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06330064

A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma after checkpoint inhibitor therapy receive autologous lifileucel, tumor-derived T cells expanded to attack cancer cells. Treatment includes tumor harvest, fludarabine/cyclophosphamide lymphodepletion, a single lifileucel infusion, and up to six doses of interleukin-2.

ClinicalTrials.gov ID: NCT07288073

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Cutaneous Squamous Cell Carcinoma Patients Progressing on or Intolerant to Systemic Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced cutaneous squamous cell carcinoma that has progressed on or is intolerant to checkpoint inhibitors, and who have injectable lesions but no visceral metastases, receive intratumoral L19IL2 plus L19TNF weekly for up to four weeks. Both agents target the extra-domain B of fibronectin in tumor tissue, delivering IL-2 to stimulate cytotoxic immune cells and TNF locally.

ClinicalTrials.gov ID: NCT07228442

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with unresectable or metastatic melanoma, recurrent or metastatic head and neck squamous cell carcinoma, or stage III–IV non-small cell lung cancer receive autologous tumor-infiltrating lymphocytes (lifileucel/LN-144, LN-145, or PD-1-selected LN-145-S1) after lymphodepleting chemotherapy, followed by aldesleukin. Depending on the cohort, treatment is given alone or with checkpoint inhibitors; some frontline lung cancer cohorts also receive platinum-doublet chemotherapy plus pembrolizumab.

ClinicalTrials.gov ID: NCT03645928

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors and ECOG performance status 0–1 receive MDNA11 alone or with pembrolizumab. MDNA11 is a long-acting IL-2 agonist designed to favor IL-2 receptor β signaling in CD8-positive T cells and natural killer cells while limiting regulatory T-cell stimulation; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT05086692

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, recurrent unresectable, locally advanced, or metastatic EGFR-expressing solid tumors are eligible if they are germline HLA-A*02 heterozygous and their tumors have lost HLA-A*02 expression. After lymphodepleting chemotherapy, patients receive a single infusion of A2B395, an allogeneic CAR T-cell therapy designed to target EGFR-positive cells while sparing healthy cells that retain HLA-A*02.

ClinicalTrials.gov ID: NCT06682793

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors that have progressed after standard therapy receive IV SMP-3124LP, a PEGylated liposomal CHK1 inhibitor targeting the DNA-damage response. Dose escalation includes several tumor types; expansion focuses on platinum-resistant ovarian cancer, triple-negative breast cancer, and anal squamous cell carcinoma.

ClinicalTrials.gov ID: NCT06526819

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors (ECOG 0–1) and injectable lesions receive intratumoral tolododekin alfa (ANK-101), an alum-binding interleukin-12 therapy designed to retain IL-12 in the tumor and stimulate local immune responses. Expansion cohorts include patients with stage III–IV non-small cell lung cancer with injectable visceral lesions and patients with unresectable high-risk locally advanced or metastatic cutaneous squamous cell carcinoma, who receive ANK-101 plus the PD-1 inhibitor cemiplimab.

ClinicalTrials.gov ID: NCT06171750

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic melanoma, head and neck squamous cell carcinoma, non-small-cell lung cancer, triple-negative breast cancer, or classical Hodgkin lymphoma receive intravenous CTX-8371 monotherapy every 2 weeks. CTX-8371 is a bispecific antibody targeting PD-1 and PD-L1; most solid-tumor cohorts require progression after prior PD-1/PD-L1 therapy.

ClinicalTrials.gov ID: NCT06150664